Sotera Health (SHC) to Post Quarterly Earnings on Thursday

Sotera Health (NASDAQ:SHCGet Free Report) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Sotera Health to announce earnings of $0.2389 per share and revenue of $309.6980 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:00 AM ET.

Sotera Health (NASDAQ:SHCGet Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.01. Sotera Health had a return on equity of 39.73% and a net margin of 9.91%.The firm had revenue of $280.05 million during the quarter, compared to analyst estimates of $270.78 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. The company’s revenue was up 10.0% compared to the same quarter last year. On average, analysts expect Sotera Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sotera Health Price Performance

SHC opened at $17.99 on Tuesday. The stock has a 50-day moving average price of $16.91 and a 200-day moving average price of $16.33. Sotera Health has a 12-month low of $11.00 and a 12-month high of $19.85. The company has a current ratio of 2.82, a quick ratio of 2.54 and a debt-to-equity ratio of 3.56. The stock has a market capitalization of $5.13 billion, a P/E ratio of 43.88 and a beta of 1.77.

Wall Street Analyst Weigh In

SHC has been the subject of a number of recent research reports. Piper Sandler restated an “overweight” rating and issued a $22.00 target price (down from $24.00) on shares of Sotera Health in a research report on Wednesday, May 6th. The Goldman Sachs Group started coverage on shares of Sotera Health in a research report on Friday, June 5th. They set a “buy” rating and a $20.00 price target on the stock. Barclays lifted their price target on shares of Sotera Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. UBS Group set a $19.00 price objective on shares of Sotera Health in a report on Wednesday, June 24th. Finally, Weiss Ratings raised shares of Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 9th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.25.

View Our Latest Report on Sotera Health

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total transaction of $193,194,516.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 15.36% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Sculptor Capital LP lifted its position in shares of Sotera Health by 27.2% in the 2nd quarter. Sculptor Capital LP now owns 11,500,000 shares of the company’s stock worth $127,880,000 after purchasing an additional 2,462,489 shares during the period. Janus Henderson Group PLC increased its position in shares of Sotera Health by 4.8% during the fourth quarter. Janus Henderson Group PLC now owns 6,772,059 shares of the company’s stock valued at $119,460,000 after buying an additional 312,191 shares during the period. State Street Corp raised its stake in Sotera Health by 21.0% in the fourth quarter. State Street Corp now owns 5,965,326 shares of the company’s stock worth $105,228,000 after buying an additional 1,035,457 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Sotera Health by 11.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,160,594 shares of the company’s stock worth $91,036,000 after buying an additional 524,012 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in Sotera Health by 1,206.2% in the fourth quarter. AQR Capital Management LLC now owns 2,864,106 shares of the company’s stock worth $50,523,000 after buying an additional 2,644,831 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Company Profile

(Get Free Report)

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

Featured Stories

Earnings History for Sotera Health (NASDAQ:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.